368 related articles for article (PubMed ID: 26857837)
1. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
Li L; Pilo GM; Li X; Cigliano A; Latte G; Che L; Joseph C; Mela M; Wang C; Jiang L; Ribback S; Simile MM; Pascale RM; Dombrowski F; Evert M; Semenkovich CF; Chen X; Calvisi DF
J Hepatol; 2016 Feb; 64(2):333-341. PubMed ID: 26476289
[TBL] [Abstract][Full Text] [Related]
4. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
5. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.
Wang C; Cigliano A; Delogu S; Armbruster J; Dombrowski F; Evert M; Chen X; Calvisi DF
Cell Cycle; 2013 Jul; 12(13):1999-2010. PubMed ID: 23759595
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Qiu Z; Zhang C; Zhou J; Hu J; Sheng L; Li X; Chen L; Li X; Deng X; Zheng G
Mol Carcinog; 2019 Jan; 58(1):31-41. PubMed ID: 30182439
[TBL] [Abstract][Full Text] [Related]
7. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.
Wang C; Che L; Hu J; Zhang S; Jiang L; Latte G; Demartis MI; Tao J; Gui B; Pilo MG; Ribback S; Dombrowski F; Evert M; Calvisi DF; Chen X
Liver Int; 2016 Aug; 36(8):1176-86. PubMed ID: 26716908
[TBL] [Abstract][Full Text] [Related]
8. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
Xu Z; Hu J; Cao H; Pilo MG; Cigliano A; Shao Z; Xu M; Ribback S; Dombrowski F; Calvisi DF; Chen X
Exp Mol Med; 2018 Jan; 50(1):e417. PubMed ID: 29303510
[TBL] [Abstract][Full Text] [Related]
9. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
Evert M; Calvisi DF; Evert K; De Murtas V; Gasparetti G; Mattu S; Destefanis G; Ladu S; Zimmermann A; Delogu S; Thiel S; Thiele A; Ribback S; Dombrowski F
Hepatology; 2012 May; 55(5):1473-84. PubMed ID: 22271091
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
[TBL] [Abstract][Full Text] [Related]
11. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation.
Mo Y; Wu Y; Li X; Rao H; Tian X; Wu D; Qiu Z; Zheng G; Hu J
Eur J Pharmacol; 2020 Jan; 867():172788. PubMed ID: 31712058
[TBL] [Abstract][Full Text] [Related]
12. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
[TBL] [Abstract][Full Text] [Related]
13. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
Che L; Pilo MG; Cigliano A; Latte G; Simile MM; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
Cell Cycle; 2017 Mar; 16(6):499-507. PubMed ID: 28118080
[TBL] [Abstract][Full Text] [Related]
14. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
[TBL] [Abstract][Full Text] [Related]
15. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
16. Improvement of mTORC1-driven overproduction of apoB-containing triacylglyceride-rich lipoproteins by short-chain fatty acids, 4-phenylbutyric acid and (R)-α-lipoic acid, in human hepatocellular carcinoma cells.
Roberts JL; He B; Erickson A; Moreau R
Biochim Biophys Acta; 2016 Mar; 1861(3):166-76. PubMed ID: 26680362
[TBL] [Abstract][Full Text] [Related]
17. Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met.
Zhang C; Sheng L; Yuan M; Hu J; Meng Y; Wu Y; Chen L; Yu H; Li S; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2020 Apr; 392():114918. PubMed ID: 32045588
[TBL] [Abstract][Full Text] [Related]
18. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways.
Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
[TBL] [Abstract][Full Text] [Related]
19. Dual regulation of fatty acid synthase (FASN) expression by O-GlcNAc transferase (OGT) and mTOR pathway in proliferating liver cancer cells.
Raab S; Gadault A; Very N; Decourcelle A; Baldini S; Schulz C; Mortuaire M; Lemaire Q; Hardivillé S; Dehennaut V; El Yazidi-Belkoura I; Vercoutter-Edouart AS; Panasyuk G; Lefebvre T
Cell Mol Life Sci; 2021 Jul; 78(13):5397-5413. PubMed ID: 34046694
[TBL] [Abstract][Full Text] [Related]
20. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]